Evidence map›Paper›PMID 40240506›Full record

ArticleScientific reports2025

Detection of the GH analogue somatrogon in doping control urine samples by means of LC-HRMS/MS.

Katja Walpurgis, Andreas Thomas, Alexandra Rauer, Bettina Majer, Mitsuhiko Sato, Masato Okano, Maneera Al-Jaber, Wadha Abushareeda, Cristian-Gabriel Arsene, Hans Geyer and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. New directions in growth hormone treatment in children.Pediatric endocrinology, diabetes, and metabolism · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katja WalpurgisInstitute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany. k.walpurgis@biochem.dshs-koeln.de.
Andreas ThomasInstitute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Alexandra RauerInstitute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Bettina MajerInstitute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Mitsuhiko SatoAnti-Doping Laboratory, LSI Medience Corporation, Tokyo, Japan.
Masato OkanoAnti-Doping Laboratory, LSI Medience Corporation, Tokyo, Japan.
Maneera Al-JaberAnti-Doping Lab Qatar, Doha, Qatar.
Wadha AbushareedaAnti-Doping Lab Qatar, Doha, Qatar.
Cristian-Gabriel ArsenePhysikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany.
Hans GeyerInstitute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Mario ThevisInstitute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatrogon is a synthetic growth hormone (GH) analog, whose misuse in sports is prohibited at all times. As analytical approaches complementary to existing immunological GH detection methods were considered beneficial for its detection in doping control serum samples, a sensitive and specific qualitative mass spectrometric assay was recently developed, comprehensively characterized, and successfully employed to analyze authentic in vivo study samples. Within this follow-up project, this approach based on affinity purification, tryptic digestion, and LC-HRMS/MS was modified by implementing an additional ultrafiltration step to allow for the extraction of the intact drug and/or its metabolites from urine. Method validation demonstrated its specificity and sensitivity (LOD: 1 ng/mL), and the subsequent analysis of post-administration urine samples showed for the first time that intact (or at least GH receptor binding) somatrogon is excreted into urine and can be detected in most subjects for at least 96 h following injection. Consequently, anti-doping laboratories can also use urine to confirm the presence of somatrogon in athletes, where the GH differential isoform assay yielded atypical results in the corresponding serum specimens. Moreover, the latter assay also proved to be valuable as screening tool for the identification of urine samples potentially containing the GH analog.

Indexed as

Doping in SportsGrowth HormoneHuman Growth HormoneSubstance Abuse DetectionTandem Mass SpectrometryChromatography, LiquidHumansMaleGrowth HormoneHuman Growth HormonesomatrogonAffinity purificationDopingGrowth hormone analogueLC-HRMS/MSTryptic digestionUltrafiltrationUrine

Identifiers

PMID40240506
PMCPMC12003886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.